Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice.

Type of the program: multicenter, observational, uncontrolled, open program. The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities.Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

Multicenter observational open program. Assessment of the efficacy and tolerability of the fixed-dose combination of bisoprolol/perindopril in patients with arterial hypertension and stable CAD in daily clinical practice (STYLE)

Study objectives and purposes:

Primary endpoints:

• efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice regarding the BP
• efficacy of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice regarding the angina

Secondary endpoints:

• impact on the quality of life of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice
• adherence to bisoprolol/perindopril FDC therapy in patients with HT and stable CAD in everyday practice The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities. Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

Milestones of the program:

FSI - November, 2018 LSLV- January, 2019 Database Lock - February, 2019 Statistic Report- May, 2019 Clinical Study Report- January, 2020

Inclusion Criteria:

• Stable CAD, defined as stable angina pectoris of class 1-3 by CCS (Canadian Cardiovascular Society) classification;
• Previously or newly diagnosed essential hypertension
• Age 18 to 79 years old;
• Informed consent of the patient for participation in the program;
• Decision of the doctor to prescribe bisoprolol/perindopril FDC before the inclusion in the program in accordance to the instruction for use.

Exclusion Criteria:

• Stable angina pectoris, class 4;
• History of myocardial infarction or cerebrovascular event within the past 3 months;
• Unstable angina within the past 6 months;
• Chronic heart failure classes 3-4 (NYHA);
• Type 1 diabetes mellitus or decompensated type 2 diabetes mellitus;
• Any serious decompensated concomitant diseases requiring the regular medical therapy;
• Inability to understand the essence of the program and follow the recommendations;
• Contraindications to beta-blockers or ACE inhibitors using;
• Participation of the patient in other trials in the present time or within 30 days before the start of observational program.

It is planned to include into the program the patients with HT and concomitant stable CAD. It is planned to include not less than 1920 patients in total.

The patient is included in the program, if the doctor decides to prescribe FDC with beta-blocker bisoprolol and ACE inhibitor perindopril in accordance to the instruction for use.

The sponsor reserves the exclusive right to all materials, information, unpublished documentation, results and information obtained during the research. The Sponsor reserves the right to send research data to the health authorities (individual registration cards, analysis results, reports).

No unpublished documentation or information transmitted to researchers can be transferred to unauthorized persons without the prior written consent of Sponsor.

1909 patients were included however 17 were excluded from the population analysed due to violation of inclusion creteria. Therefore full analysis set is 1892.

3 month

Were registered 9 AEs in 4 patients, of which 3 patients had adverse drug reactions resulting in the withdrawal from treatment. 1 patient started to take the study drug periodically and not daily, which did not comply with the instructions for the medical use of the drug.